EUVIMEDEUVIMED entdecken
Multizentrische Studie

Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

Edoxaban, Rivaroxaban oder Apixaban bei krebsassoziierter venöser Thromboembolie in der Praxis: Erkenntnisse aus dem COMMAND VTE Registry-2

Daisuke Sueta iD, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Yuji Nishimoto, Kazuhisa Kaneda, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase und 24 weitere

Thrombosis and Haemostasis · 2024-11 · 124 (11) · 1013-1023

DOI: 10.1055/a-2316-5269 ↗

Auf einen Blick

Bei 1.197 Patient:innen mit aktivem Krebs unterschieden sich rezidivierende VTE und Gesamtmortalität zwischen Edoxaban, Rivaroxaban und Apixaban nicht. Blutungsereignisse traten unter Rivaroxaban seltener auf.

Fragestellung

Unterscheiden sich Wirksamkeit und Sicherheit von Edoxaban, Rivaroxaban und Apixaban bei krebsassoziierter venöser Thromboembolie im Praxisalltag?

Methode

Multizentrisches Register mit 1.197 Patient:innen mit aktivem Krebs und akuter symptomatischer VTE aus 31 Zentren in Japan; Vergleich von Edoxaban, Rivaroxaban und Apixaban.

Ergebnisse

Rezidivierende VTE nach 5 Jahren: 9,3 %, 10,2 % und 8,5 % (p = 0,82). Gesamtmortalität: 67,5 %, 66,8 % und 63,8 % (p = 0,22). Major Bleeding: 22,6 %, 14,0 % und 22,8 % (p = 0,04).

Schlussfolgerung der Autor:innen

Das Risiko für rezidivierende VTE und Gesamtmortalität unterschied sich zwischen den DOACs nicht signifikant; Blutungsereignisse könnten sich unterscheiden, mit potenziell geringerem Blutungsrisiko unter Rivaroxaban.

Kernaussagen

  • Rezidivierende VTE und Gesamtmortalität unterschieden sich nicht signifikant.
  • Major und klinisch relevante Blutungen waren unter Rivaroxaban seltener.
  • Adjustierte Analyse: klinisch relevante Blutungen unter Rivaroxaban geringer als unter Edoxaban.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 24.05.2024. Verfasst von Daisuke Sueta und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Pyrazoles, Pyridines, Pyridones, Registries. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan., Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data on clinical characteristics and outcomes related to the use of different direct oral anticoagulants (DOACs) for cancer-associated venous thromboembolism (VTE) is lacking.

Methods

The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive patients with acute symptomatic VTE from 31 centers in Japan from January 2015 to August 2020. Our study population comprised 1,197 patients with active cancer who were divided into the edoxaban (N = 643, 54%), rivaroxaban (N = 297, 25%), and apixaban (N = 257, 22%) groups.

Results

The cumulative 5-year incidence of recurrent VTE (9.3, 10.2, and 8.5%, respectively, p = 0.82) and all-cause death (67.5, 66.8, and 63.8%, respectively, p = 0.22) did not differ among the groups. Despite adjusting for confounders, the risks of recurrent VTE and all-cause death did not differ significantly among the groups. The cumulative 5-year incidence of major and clinically relevant bleeding was significantly lower in the rivaroxaban group than those in the other groups (22.6, 14.0, and 22.8%, p = 0.04; and 37.6, 26.8, and 38.3%, p = 0.01, respectively). After adjusting for confounders, in the rivaroxaban group, the risk for major bleeding was numerically lower (hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.40–1.01) and that of clinically relevant all bleeding was significantly lower (HR: 0.67, 95% CI: 0.48–0.92) than those in the edoxaban group.

Conclusion

The risks of recurrent VTE and all-cause death did not differ significantly among the different DOACs ; however, the risk of bleeding events could differ, with a potentially lower risk of bleeding with rivaroxaban.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPyridinesPyridonesRegistriesRivaroxabanThiazolesVenous ThromboembolismAgedAged, 80 and overFemaleHumansMaleMiddle AgedFactor Xa InhibitorsHemorrhageIncidenceJapanNeoplasmsRecurrenceRisk FactorsTreatment Outcome

Substanzen

apixabanedoxabanFactor Xa InhibitorsPyrazolesPyridinesPyridonesRivaroxabanThiazoles

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan.
  • Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
  • Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
  • Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.

ORCID-Profile: Daisuke Sueta

Förderung

  • Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
  • Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Sueta, D., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Kaneda, K., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., Takase, T., Tsuji, S., Oi, M., Takada, T., Otsui, K., Sakamoto, J., Ogihara, Y., Inoue, T., …, & COMMAND VTE Registry-2 Investigators (2024). Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2. Thrombosis and Haemostasis, 124(11), 1013-1023. https://doi.org/10.1055/a-2316-5269

Vancouver

Sueta D, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Kaneda K, et al. Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2. Thrombosis and Haemostasis. 2024;124(11):1013-1023. doi:10.1055/a-2316-5269

BibTeX
@article{Sueta2024,
  author = {Sueta, Daisuke and Yamashita, Yugo and Morimoto, Takeshi and Chatani, Ryuki and Nishimoto, Yuji and Kaneda, Kazuhisa and Ikeda, Nobutaka and Kobayashi, Yohei and Ikeda, Satoshi and Kim, Kitae and Inoko, Moriaki and Takase, Toru and Tsuji, Shuhei and Oi, Maki and Takada, Takuma and Otsui, Kazunori and Sakamoto, Jiro and Ogihara, Yoshito and Inoue, Takeshi and Usami, Shunsuke and Chen, Po-Min and Togi, Kiyonori and Koitabashi, Norimichi and Hiramori, Seiichi and Doi, Kosuke and Mabuchi, Hiroshi and Tsuyuki, Yoshiaki and Murata, Koichiro and Takabayashi, Kensuke and Nakai, Hisato and Shioyama, Wataru and Dohke, Tomohiro and Nishikawa, Ryusuke and Kimura, Takeshi and Tsujita, Kenichi and COMMAND VTE Registry-2 Investigators, COMMAND VTE Registry-2 Investigators},
  title = {Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {11},
  pages = {1013--1023},
  doi = {10.1055/a-2316-5269}
}
Kostenlos starten →